THAR_logo-min
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

Don't miss out! Sign up below to learn more about this investment opportunity.

Don't miss out! Sign up below to learn more about this investment opportunity.

By signing up above, Wall Street Fundamentals will send the latest investor report to the email provided. You'll also receive special reports completely free. You can unsubscribe at any time. View our Privacy Policy here.

Don't miss out! Sign up below to learn more about this investment opportunity.

By signing up above you’ll receive the free report from WallStreetFundamentals.com as well as other actionable investment ideas and market commentary! Of course, you may unsubscribe at any time.

ADVERTISEMENT DISCLAIMER

THIS PUBLICATION IS AN ISSUER-PAID ADVERTISEMENT. This paid advertisement includes a stock profile of Tharimmune (THAR). To enhance public awareness of THAR and its securities, the issuer has provided Promethean Marketing, Inc. (“Promethean”) with a total budget of approximately one hundred seventy thousand dollars ($170,000.00) USD to cover the costs associated with this advertisement for a period beginning 7 July 2024 and currently set to end 8 August 2024. This compensation should be viewed as a major conflict with our ability to be unbiased. The website hosting this advertisement, Wall Street Fundamentals, is owned by Promethean. As a result of this advertisement, Wall Street Fundamentals may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. Promethean will retain any excess sums after all expenses are paid. As of the date this advertisement is posted to the Wall Street Fundamentals website, some or all of Promethean or Wall Street Fundamentals and any of their respective officers, principals, or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) may hold the securities of THAR and may sell those shares during the course of this advertising campaign. This advertisement may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of THAR, increased trading volume, and possibly an increased share price of THAR’s securities, which may or may not be temporary and decrease once the advertising campaign has ended. This communication is based on information generally available to the public and on interviews with THAR Management, and does not (to the Publisher’s knowledge, as confirmed by THAR) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, neither Promethean or Wall Street Fundamentals cannot guarantee the accuracy or completeness of the information. To more fully understand the Wall Street Fundamentals website or service, please review its full Disclaimer and Disclosure Policy located here.

[25] https://d1io3yog0oux5.cloudfront.net/_46a1d14013bd2ce09a5272ad19353483/upexi/db/2265/21364/pdf/UPEXI+IR+05_05_23.pdf

Copyright @ 2024 WallStreetFundamentals.com. All Rights Reserved.
Scroll to Top

Learn More About This Exciting Investment Opportunity!

Enter your email below and receive the full investor presentation.

Free Bonus: Actionable investment ideas and commentary delivered right to your inbox.

 By signing up below you will receive the free Wall Street Fundamentals newsletter. You can unsubscribe at any time, view our Privacy Policy here.